High Productivity Downstream Purifications

Global demand for cheaper biotherapeutics, which represent many of the new tools in the fight against diseases such as cancer, drives the need for a reduction in manufacturing costs. A significant proportion of current costs arise from the purification technologies currently used to ensure the safety and efficacy of these treatments. Improvements to these technologies are
fundamentally limited with the existing dominant technology reaching a point where it is unable to match performance increases in the rest of the manufacturing process. This will impact the ability for drug manufacturers to reach economies of scale and meet market demands from patients.
Puridify’s novel nanofibre purification technology has the potential to revolutionise the industrial scale production of biotherapeutics. The material’s properties can overcome current manufacturing limitations by increasing productivity 10-fold, potentially reducing biotherapeutic manufacturing costs by up to 25%. This will play an important role in
widening patient access to expensive drugs in both the UK and worldwide. Puridify seeks to develop and test a basic scale-up prototype under a Proof of Concept study.
Key Aims:
1. Develop a route to large-scale manufacture based on existing research scale device and file accompanying IP
2. Investigate production and assembly of industrial scale basic prototype device to house the reagent.
3. Test at the required industrial scale to provide basic proof of technical feasibility.
The goal is to demonstrate to the market the potential of our novel reagent material to reduce manufacturing costs by up to 25% while proving the robustness of our material, a key purchase decision factor for purification materials.